Audience responses to psoriasis treatment target and priorities questions. Responses are n (%).
| 1. What is your primary role? (Total responses N = 125) | |
| a. Psoriasis researcher/healthcare provider | 28 (22) |
| b. PsA researcher/healthcare provider | 88 (70) |
| c. Patient/patient advocate | 9 (7) |
| 2. What is an appropriate target regarding change in PASI? (N = 149) | |
| a. ≥ PASI75 | 84 (56) |
| b. ≥ PASI90 | 54 (36) |
| c. PASI100 | 11 (7) |
| 3. What is an appropriate target regarding BSA? (N = 148) | |
| a. ≤ 10% | 11 (7) |
| b. ≤ 5% | 17 (11) |
| c. ≤ 3% | 48 (32) |
| d. ≤ 1% | 64 (43) |
| e. 0% | 8 (5) |
| 4. What is an appropriate target regarding PGA? (N = 152) | |
| a. At most mild (i.e., mild, almost clear, or clear) | 16 (11) |
| b. At most almost clear (i.e., almost clear or clear) | 99 (65) |
| c. Clear | 37 (24) |
| 5. What is an appropriate target regarding DLQI? (N = 135) | |
| a. ≤ 5 (i.e., no to small effect on QoL) | 24 (18) |
| b. ≤ 1 (i.e., no effect on QoL) | 93 (69) |
| c. 0 (i.e., no effect on QoL) | 18 (13) |
| 6. This is how I would prioritize “targets” in the treat-to-target approach (N = 137) | |
| a. Psoriasis disease activity > QoL > PsA disease activity | 2 (1) |
| b. Psoriasis disease activity > PsA disease activity > QoL | 8 (6) |
| c. QoL > psoriasis disease activity > PsA disease activity | 21 (15) |
| d. QoL > PsA disease activity > psoriasis disease activity | 62 (45) |
| e. PsA disease activity > psoriasis disease activity > QoL | 23 (17) |
| f. PsA disease activity > QoL > psoriasis disease activity | 21 (15) |
PsA: psoriatic arthritis; PASI: Psoriasis Area and Severity Index; BSA: body surface area; QoL: quality of life; DLQI: Dermatology Life Quality Index; PGA: physician’s global assessment.